

118TH CONGRESS
2D SESSION

S. 4436

To improve the safety of infant formula through testing of infant formula for microorganisms and toxic elements, and for other purposes.

IN THE SENATE OF THE UNITED STATES

JUNE 3, 2024

Mr. PETERS (for himself and Mr. HOEVEN) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To improve the safety of infant formula through testing of infant formula for microorganisms and toxic elements, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the “Protect Infant For-
5 mula from Contamination Act”.

6 SEC. 2. MANDATING TESTING OF INFANT FORMULA.

7 Section 412(e) of the Federal Food, Drug, and Cos-
8 metic Act (21 U.S.C. 350a(e)) is amended—

1 (1) in paragraph (1), in the matter following
2 subparagraph (B)—

3 (A) by striking “promptly”;
4 (B) by inserting “, within 24 hours of ac-
5 quiring such knowledge” after “such knowl-
6 edge”; and

7 (C) by striking “the infant formula” and
8 inserting “an infant formula”;

9 (2) by redesignating paragraph (2) as para-
10 graph (5);

11 (3) in paragraph (5), as so redesignated, by
12 striking “paragraph (1)” and inserting “paragraphs
13 (1) and (2)”; and

14 (4) by inserting after paragraph (1) the fol-
15 lowing:

16 “(2) If the result of any testing of a sample from
17 any production aggregate of finished infant formula prod-
18 uct is confirmed as a positive analytical result for any
19 microorganism for which finished product testing is re-
20 quired under section 106.55(e) of title 21, Code of Federal
21 Regulations (or any successor regulation), the manufac-
22 turer shall—

23 “(A) within 24 hours of acquiring a confirmed
24 positive analytical result, notify the Secretary of
25 such knowledge, regardless of whether such product

1 has left an establishment subject to the control of
2 the manufacturer;

3 “(B) promptly consult with the Secretary for
4 proper isolation of the affected product, and, as the
5 Secretary may require, cease distribution and prop-
6 erly dispose of the affected product; and

7 “(C) promptly provide to the Secretary results
8 and isolates from a positive sample of such product.

9 “(3) Not later than 72 hours after receipt by the Sec-
10 retary of a notification under paragraph (2)(A), the Sec-
11 retary shall respond to the manufacturer of the infant for-
12 mula to begin discussions regarding investigation and cor-
13 rective action, and, as appropriate, share the findings of
14 the Secretary with the manufacturer.

15 “(4) Not later than 90 days after receipt of a notifi-
16 cation under paragraph (1) or (2), the Secretary shall con-
17 firm, including through the collection of documentation,
18 that the manufacturer submitting the notification per-
19 formed, or is performing, an appropriate investigation and
20 corrective action, if applicable. The Secretary shall con-
21 sider, as part of the review of the root cause investigation,
22 the analytical method used to conduct laboratory testing
23 and, as appropriate, the potential for cross contamination
24 of the sample by handling and testing. The manufacturer
25 shall make such documentation available to the Secretary

1 electronically or by other means, if requested by the Sec-
2 retary.”.

3 **SEC. 3. REPORTING TO IMPROVE THE SAFETY AND SUPPLY**

4 **OF INFANT FORMULA.**

5 Section 412 of the Federal Food, Drug, and Cosmetic
6 Act (21 U.S.C. 350a) is amended by adding at the end
7 the following:

8 “(n) REPORTING TO IMPROVE THE SAFETY AND
9 SUPPLY OF INFANT FORMULA.—

10 “(1) PROGRESS REPORT.—Not later than 180
11 days after the date of enactment of the Protect In-
12 fant Formula from Contamination Act, the Sec-
13 retary shall issue a progress report on implemen-
14 tation of the recommendations to improve the safety
15 and supply of infant formula contained in the report
16 titled, ‘Immediate National Strategy to Increase the
17 Resiliency of the U.S. Infant Formula Market’,
18 issued by the Food and Drug Administration in
19 March 2023. Such progress report shall include ad-
20 ditional authorities or resources that the Secretary
21 may require for purposes of improving the safety
22 and supply of infant formula.

23 “(2) QUARTERLY REPORTS ON SUPPLY
24 CHAIN.—Not later than 270 days after the date of
25 enactment of the Protect Infant Formula from Con-

1 tamination Act, and not less frequently than quarterly
2 for the 5-year period thereafter, the Secretary
3 shall submit a report on the most current, critical
4 supply chain data for infant formula, including in-
5 stock rates, to—

6 “(A) the Committee on Health, Education,
7 Labor, and Pensions; the Committee on Agriculture,
8 Nutrition, and Forestry; and the Sub-
9 committee on Agriculture, Rural Development,
10 Food and Drug Administration, and Related
11 Agencies of the Committee on Appropriations of
12 the Senate; and

13 “(B) the Committee on Energy and Com-
14 merce; the Committee on Agriculture; and the
15 Subcommittee on Agriculture, Rural Develop-
16 ment, Food and Drug Administration, and Re-
17 lated Agencies of the Committee on Appropria-
18 tions of the House of Representatives.

19 “(3) CONSULTATION.—The Secretary, in ac-
20 cordance with the National Strategy set forth in the
21 report described in paragraph (1), shall engage with
22 the Department of Agriculture and other relevant
23 agencies of the Federal Government regarding ongoing
24 efforts to address immediate formula needs and

1 build long-term resiliency into the infant formula
2 market.

3 “(4) ANNUAL REPORTS ON ADEQUACY OF SUP-
4 PPLY.—Not later than 270 days after the date of en-
5 actment of the Protect Infant Formula from Con-
6 tamination Act, and not less frequently than annu-
7 ally for the 5-year period thereafter, the Secretary
8 shall—

9 “(A) engage with infant formula manufac-
10 turers to determine evidence-based practices
11 that can be implemented to maximize infant
12 formula supply and infant safety, including the
13 value of high frequency testing in identifying
14 contamination events and bracketing potentially
15 contaminated product, the impact of corrective
16 action on contamination events, and evidence-
17 based recommendations for enhancing infant
18 formula supply and safety; and

19 “(B) submit a report to the committees de-
20 scribed in subparagraphs (A) and (B) of para-
21 graph (2) that identifies the modifications to
22 manufacturer practices and actions described in
23 subparagraph (A), if any, that could be imple-

1 mented to improve infant formula supply and
2 safety.”.

